...
首页> 外文期刊>Toxicology in vitro: an international journal published in association with BIBRA >Transfer of a two-tiered keratinocyte assay: IL-18 production by NCTC2544 to determine the skin sensitizing capacity and epidermal equivalent assay to determine sensitizer potency
【24h】

Transfer of a two-tiered keratinocyte assay: IL-18 production by NCTC2544 to determine the skin sensitizing capacity and epidermal equivalent assay to determine sensitizer potency

机译:两层角质形成细胞测定的转移:通过NCTC2544产生IL-18来确定皮肤敏化能力,并通过表皮等效测定来确定敏化剂效力

获取原文
获取原文并翻译 | 示例
           

摘要

At present, the identification of potentially sensitizing chemicals is carried out using animal models. However, it is very important from ethical, safety and economic point of view to have biological markers to discriminate allergy and irritation events, and to be able to classify sensitizers according to their potency, without the use of animals. Within the Sens-it-iv EU Frame Programme 6 funded Integrated Project (LSHB-CT-2005-018681), a number of in vitro, human cell based assays were developed which, when optimized and used in an integrated testing strategy, may be able to distinguish sensitizers from non-sensitizers. This study describes two of these assays, which when used in a tiered strategy, may be able to identify contact sensitizers and also to quantify sensitizer potency. Tier 1 is the human keratinocyte NCTC2544 IL-18 assay and tier 2 is the Epidermal Equivalent potency assay. The aim of this study is to show the transferability of the two-tiered approach with training chemicals: 3 sensitizers (DNCB, resorcinol, pPD) and 1 non sensitizer (lactic acid) in tier 1 and 2 sensitizers with different potency in tier 2 (DNCB; extreme and resorcinol; moderate). The chemicals were tested in a non-coded fashion. Here we describe the transferability to na?ve laboratories, the establishment of the standard operating procedure, critical points, acceptance criteria and project management. Both assays were successfully transferred to laboratories that had not performed the assays previously. The two tiered approach may offer an unique opportunity to provide an alternative method to the Local Lymph Node Assay (LLNA). These assays are both based on the use of human keratinocytes, which have been shown over the last two decades, to play a key role in all phases of skin sensitization.
机译:目前,使用动物模型进行潜在致敏化学物质的鉴定。但是,从伦理,安全和经济的角度来看,具有生物标记物来区分过敏和刺激事件,并且能够根据其效价对敏化剂进行分类而无需使用动物,这是非常重要的。在由Sens-it-iv欧盟框架计划6资助的集成项目(LSHB-CT-2005-018681)中,开发了许多基于体外,基于人细胞的分析方法,这些方法在进行优化并用于集成测试策略时,可能会能够区分敏化剂和非敏化剂。这项研究描述了其中的两种测定法,当它们用于分层策略时,它们可能能够识别接触敏化剂并量化敏化剂的效力。方法1是人角质形成细胞NCTC2544 IL-18分析,方法2是表皮等效效力分析。这项研究的目的是展示两层方法与培训化学品的可转移性:1级使用3种敏化剂(DNCB,间苯二酚,pPD)和1种非敏化剂(乳酸),而2级使用两种效价不同的敏化剂( DNCB;极度和间苯二酚;中度)。化学药品以非编码方式进行了测试。在这里,我们描述了可移植到天然实验室的能力,标准操作程序的建立,关键点,验收标准和项目管理。两种测定均成功转移到以前未进行过测定的实验室。两层方法可能会提供独特的机会,为本地淋巴结分析(LLNA)提供替代方法。这些测定都是基于人类角质形成细胞的使用,在过去的二十年中已经显示,它们在皮肤敏化的所有阶段都起着关键作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号